BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,946,159 | +4.7% | 73,802 | -32.5% | 0.00% | -33.3% |
| Q2 2023 | $1,858,706 | +40289.1% | 109,400 | -59.2% | 0.00% | -57.1% |
| Q1 2023 | $4,602 | +2361.0% | 268,300 | +995.1% | 0.01% | – |
| Q4 2022 | $187 | -99.9% | 24,500 | +72.5% | 0.00% | – |
| Q1 2022 | $147,000 | -83.7% | 14,200 | -77.1% | 0.00% | -100.0% |
| Q4 2021 | $904,000 | -49.6% | 62,100 | +64.7% | 0.00% | -50.0% |
| Q3 2021 | $1,795,000 | -16.4% | 37,700 | +5.6% | 0.00% | -33.3% |
| Q2 2021 | $2,146,000 | +144.1% | 35,700 | +140.0% | 0.00% | +200.0% |
| Q1 2021 | $879,000 | – | 14,878 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |